Parnetti L - Search Results

1

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. Parnetti L, et al. Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Lancet Neurol. 2019. PMID: 30981640 Review.

2

Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.

Bråne G, Gottfries CG, Blennow K, Karlsson I, Lekman A, Parnetti L, Svennerholm L, Wallin A. Bråne G, et al. Among authors: parnetti l. Alzheimer Dis Assoc Disord. 1989 Fall;3(3):148-56. doi: 10.1097/00002093-198903030-00004. Alzheimer Dis Assoc Disord. 1989. PMID: 2477044

3

Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia.

Parnetti L, Reboldi GP, Gallai V. Parnetti L, et al. Neurology. 2000 Feb 8;54(3):735-7. doi: 10.1212/wnl.54.3.735. Neurology. 2000. PMID: 10680813

4

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F; Phospho-Tau International Study Group. Parnetti L, et al. Neurol Sci. 2001 Feb;22(1):77-8. doi: 10.1007/s100720170055. Neurol Sci. 2001. PMID: 11487210

5

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V. Parnetti L, et al. Neurol Sci. 2002 Sep;23 Suppl 2:S95-6. doi: 10.1007/s100720200086. Neurol Sci. 2002. PMID: 12548360 Clinical Trial.

6

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

Sáez-Valero J, Fodero LR, Sjögren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Sáez-Valero J, et al. Among authors: parnetti l. J Neurosci Res. 2003 May 15;72(4):520-6. doi: 10.1002/jnr.10599. J Neurosci Res. 2003. PMID: 12704813

7

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Parnetti L, et al. Mech Ageing Dev. 2006 Feb;127(2):129-32. doi: 10.1016/j.mad.2005.09.022. Epub 2005 Nov 7. Mech Ageing Dev. 2006. PMID: 16274728

8

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

Calabresi P, Picconi B, Parnetti L, Di Filippo M. Calabresi P, et al. Among authors: parnetti l. Lancet Neurol. 2006 Nov;5(11):974-83. doi: 10.1016/S1474-4422(06)70600-7. Lancet Neurol. 2006. PMID: 17052664 Review.

9

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bläser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E. Vanderstichele H, et al. Among authors: parnetti l. Clin Chem Lab Med. 2006;44(12):1472-80. doi: 10.1515/CCLM.2006.258. Clin Chem Lab Med. 2006. PMID: 17163825

10

Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease.

Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C, Orlacchio A, Calabresi P, Beccari T, Rossi A. Balducci C, et al. Among authors: parnetti l. Mov Disord. 2007 Jul 30;22(10):1481-1484. doi: 10.1002/mds.21399. Mov Disord. 2007. PMID: 17546678

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page